Update on diagnosis and treatment of multiple sclerosis

被引：1

作者：

Depaz, R. ^{[1
]}

Aboab, J. ^{[1
]}

Gout, O. ^{[1
]}

机构：

[1] Fondat Ophtalmol Adolphe de Rothschild, F-75019 Paris, France

来源：

REVUE DE MEDECINE INTERNE | 2013年 / 34卷 / 10期

关键词：

Multiple sclerosis; Neuroimaging; Diagnosis; Treatment; LONGITUDINAL FOLLOW-UP; NATURAL-HISTORY; INTERFERON-BETA; GLATIRAMER ACETATE; INTRAMUSCULAR INTERFERON; CORTICAL DEMYELINATION; DISEASE-ACTIVITY; DISABILITY; MRI; NATALIZUMAB;

D O I：

10.1016/j.revmed.2013.02.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent advances in neuroimaging have simplified the diagnostic criteria of multiple sclerosis. Indeed, the diagnosis of multiple sclerosis could be obtained during the first bout of disease flare, very early in the disease course. This is particularly important to shorten the diagnostic delay as early treatment may limit the occurrence of late irreversible disabilities. At the same time, major therapeutic advances have been obtained and new drugs that are well tolerated and more effective, despite the possible rare but potentially severe side effects are been developed. This article reviews the modern diagnostic and therapeutic strategies in multiple sclerosis in accordance with the recent obtained advances. (C) 2013 Published by Elsevier Masson SAS on behalf of the Societe nationale francaise de medecine interne (SNFMI).

引用

页码：628 / 635

页数：8

共 60 条

[11] Natural history of multiple sclerosis: a unifying concept
Confavreux, C
Vukusic, S
[J]. BRAIN, 2006, 129 : 606 - 616
[12] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
Confavreux, C
Vukusic, S
Adeleine, P
[J]. BRAIN, 2003, 126 : 770 - 782
[13] Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis
Dhib-Jalbut, S
[J]. NEUROLOGY, 2002, 58 (08) : S3 - S9
[14] Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, Ranjan
Trapp, Bruce D.
[J]. PROGRESS IN NEUROBIOLOGY, 2011, 93 (01) : 1 - 12
[15] Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
Ebers, G. C.
Traboulsee, A.
Li, D.
Langdon, D.
Reder, A. T.
Goodin, D. S.
Bogumil, T.
Beckmann, K.
Wolf, C.
Konieczny, A.
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (08) : 907 - 912
[16] Interferon β-1b and glatiramer acetate effects on permanent black hole evolution
Filippi, M.
Rocca, M. A.
Camesasca, F.
Cook, S.
O'Connor, P.
Arnason, B. G. W.
Kappos, L.
Goodin, D.
Jeffery, D.
Hartung, H. -P.
Comi, G.
Wolinsky, J. S.
Bogumil, T.
Pohl, C.
Beckmann, K.
Sandbrink, R.
Croze, E.
Brown, C.
DeSimone, T. M.
Arnold, D. L.
Cutter, G.
Knappertz, V.
[J]. NEUROLOGY, 2011, 76 (14) : 1222 - 1228
[17] Association between pathological and MRI findings in multiple sclerosis
Filippi, Massimo
Rocca, Maria A.
Barkhof, Frederik
Brueck, Wolfgang
Chen, Jacqueline T.
Comi, Giancarlo
DeLuca, Gabriele
De Stefano, Nicola
Erickson, Bradley J.
Evangelou, Nikos
Fazekas, Franz
Geurts, Jeroen J. G.
Lucchinetti, Claudia
Miller, David H.
Pelletier, Daniel
Popescu, Bogdan F. Gh
Lassmann, Hans
[J]. LANCET NEUROLOGY, 2012, 11 (04) : 349 - 360
[18] Disability and T2 MRI lesions:: a 20-year follow-up of patients with relapse onset of multiple sclerosis
Fisniku, L. K.
Brex, P. A.
Altmann, D. R.
Miszkiel, K. A.
Benton, C. E.
Lanyon, R.
Thompson, A. J.
Miller, D. H.
[J]. BRAIN, 2008, 131 : 808 - 817
[19] New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
Fox, Edward J.
Rhoades, Robert W.
[J]. CURRENT OPINION IN NEUROLOGY, 2012, 25 : S11 - S19
[20] Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, Robert J.
Miller, David H.
Phillips, J. Theodore
Hutchinson, Michael
Havrdova, Eva
Kita, Mariko
Yang, Minhua
Raghupathi, Kartik
Novas, Mark
Sweetser, Marianne T.
Viglietta, Vissia
Dawson, Katherine T.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (12) : 1087 - 1097

← 1 2 3 4 5 6 →